Shanghai Shape Memory Alloy Materials Co., Ltd. (a Wholly-owned Subsidiary of CardioTech Medical, HKEX: 2291) Receives NMPA Registration Certificate for MemoSorb® Bioresorbable Atrial Septal Defect Occluder

ScienTech Medical (02291) announced that its wholly-owned subsidiary, Shanghai Shape Memory Alloy Co., Ltd., has obtained the medical device registration certificate from the National Medical Products Administration of China for the MemoSorb® Bioresorbable Atrial Septal Occluder ("MemoSorb® Bioresorbable Atrial Septal Occluder").

MemoSorb® Bioabsorbable Atrial Septal Defect Occluder is designed to meet the needs of atrial septal defect closure, representing an innovative breakthrough that overcomes many limitations of current metal occluders. Particularly when compared with nickel-titanium alloy, the bioabsorbable polydioxanone material demonstrates better biocompatibility, significantly reduces inflammatory responses, alleviates fibrosis, and promotes endothelialization. Moreover, after the occluder degrades, atrial septal tissue regeneration is completed, preserving tissue elasticity and not affecting subsequent trans-septal interventional treatment pathways, offering greater long-term health benefits for patients. The approval and market launch of the MemoSorb® Bioabsorbable Atrial Septal Defect Occluder enriches the company’s bioabsorbable product line, and is expected to further expand the market space for congenital heart disease devices in both the Chinese and international markets, providing better options and experiences for patients with congenital heart disease.

In the future, the company will remain committed to staying at the forefront of innovation, closely focusing on clinical needs, and deeply cultivating the field of structural heart disease. It aims to develop more high-quality, high-performance products, contributing safer and more efficient medical solutions for patients in China and even globally, thereby promoting the prosperity and development of the global healthcare industry.

The sales performance of the MemoSorb® Bioabsorbable Atrial Septal Defect Occluder depends on various factors, including but not limited to clinical promotion, channel expansion, changes in the competitive landscape, and macro policies, among which the product poses uncertainties to the company’s financial performance.